Presented by Covance Chief Scientific Officer Steve Anderson, Ph.D., and Covance Global Leader, Precision Medicine and Head, Biomarker Solution Center, Suso Platero, Ph.D., this webinar will address the spectrum of immunotherapy development considerations and their implications for drug developers.
Dartmouth scientists found a therapeutic approach that should prevent the development of resistance to targeted anti-tumor drugs in gliomas
Funding supports search for new treatments for the deadliest form of cancer
CytoTest announces a significant expansion of its sales team.
QCDR Status Cements Organization's Dedication to Upholding Clinical Standards
Cancer DNA mutations can now be detected in the blood in femtogram concentrations (one femtogram = one thousand trillionth of a gram)
In this study of 5,000 women, more women who received Paclitaxel once a week were likely to be alive and free of breast cancer five years after being diagnosed compared to women who received Paclitaxel every three weeks OR women who received Docetaxel (either weekly or every three weeks).
Long-awaited Requirements Will Drive Adoption Rates in Key Markets According to Greystone Research Associates
Amber Kandur, of Highlands Oncology Group, Completed Certification Program in Healthcare Compliance
Hanson Wade, the London-based life sciences knowledge services specialist, has launched IO Combination Trials Intelligence.
Highlands Oncology Group Recognized With Corporate Sponsorship Award
Dr. Hershey Garner, of Highlands Oncology Group, Voted Best Oncologist in Northwest Arkansas By Readers' Poll
Jacques Corriveau joining as General Manager North America
Predictive Multi-Biomarkers for accelerated immuno-oncological progress
Highlands Oncology Group Voted Best of Best By Readers' Poll
Arkansas Breast Cancer Specialists is a Collaborative Effort to Ensure the Most Effective Treatments are Executed
Highlands Oncology Group Participated in 3rd Annual Screening and Care Conference Hosted By the Lung Cancer Alliance
Incoming leader brings more than 15 years of leadership experience to the role
Company Names Dr. Nick Poulios CEO
Strand NGS now supports large scale RNA- and small-RNA-Seq and Unique Molecular Identifiers (UMIs) for DNA-, RNA-, and small-RNA-Seq.
Planet TV is making it real with the work of one doctor who is ending death sentences and crushing cancer.
Highlands Oncology Group to Participate in 3rd Annual Screening and Care Conference Hosted By the Lung Cancer Alliance
Highlands Oncology Group Will Sponsor Bike Ride Benefiting The Cancer Challenge
Highlands Oncology Group Will Offer Free Prostate Cancer Screenings in October
Highlands Oncology Group Commends Two APRNs On Completing Advanced Oncological Certifications
Company will launch an AI platform and applications focused on Oncology for pharmaceutical companies and other health care partners